Comparing Sugammadex and Neostigmine for Muscle Relaxant Reversal After Lung Surgery

An Observational Study on the Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

This study is testing whether sugammadex or neostigmine works better to help patients recover from muscle relaxants after lung surgery.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 19 Years to 75 Years
• Sex: All
• Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine (other)
• Locations: 1 site (Yiwu, Zhejiang)
• Trial ID: NCT06334562 on ClinicalTrials.gov

What this trial studies

This study compares the effectiveness of sugammadex sodium and neostigmine in reversing neuromuscular blockade after thoracic surgery. Patients undergoing elective lung surgery under general anesthesia will receive either sugammadex or neostigmine after the administration of rocuronium bromide. The study will monitor recovery times of neuromuscular function and extubation, providing insights into optimizing muscle relaxant use during anesthesia. Data on dosage and recovery will be meticulously recorded to evaluate the outcomes of each reversal agent.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old undergoing elective lung surgery requiring general anesthesia and endotracheal intubation.

Not a fit: Patients with severe comorbidities or contraindications to the study medications may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved recovery times and safety for patients undergoing thoracic surgery.

How similar studies have performed: Previous studies have shown promising results with sugammadex in reversing neuromuscular blockade, indicating that this approach is supported by existing evidence.

Eligibility criteria

Inclusion Criteria:

1. Patients who undergo elective lung surgery under general anesthesia and require endotracheal intubation;
2. Age\>18 years old, gender not limited;
3. American Society of Anesthesiologists ASA Level I-III;
4. Use rocuronium bromide for neuromuscular blockade;
5. The patient voluntarily participated in the trial.

Exclusion Criteria:

1. The patient explicitly refused to participate in this trial;
2. Family history of malignant hyperthermia, patients with allergies to sodium sulbactam, neostigmine ingredients and their excipients, and patients with allergies to drugs used during general anesthesia;
3. Patients with tracheal malformations or suspected difficult airways, coagulation dysfunction, severe liver and kidney dysfunction, and severe lung disease;
4. Patients who are not extubated and sent to the ward or ICU after surgery;
5. The researchers believe that patients with any other unfavorable factors to participate in this trial.

Where this trial is running

Yiwu, Zhejiang

• The Fourth Affiliated Hospital of Zhejiang University School of Medicine — Yiwu, Zhejiang, China (RECRUITING)

Study contacts

• Principal investigator: JianHong Xu — The Fourth Affiliated Hospital of Zhejiang University School of Medicine
• Study coordinator: JianHong Xu

Conditions: Neuromuscular Blockade, Sugammadex Sodium, Postoperative Neuromuscular Block Antagonism, thoracic surgery